

# CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

## APPLICATION PEDIGREE

Date and time exported: 11/16/2023 10:51 AM CT

**FY:** 2024  
**CYCLE:** 1  
**PROGRAM:** Product Development  
**MECHANISM:** Texas Therapeutics Company Full Awards for Product Development Research  
**APPLICATION ID:** DP240073  
**APPLICATION TITLE:** Advancing Clinical Development of MB-105 CD5 CAR-T cell Therapy for T-cell Lymphoma  
**APPLICANT NAME:** Hein, Sarah  
**ORGANIZATION:** March Biosciences, Inc.  
**PANEL NAME:** 24.1 Product Development Panel-8

Category	Compliance Requirement	Information	Attestation Date	
<b>Pre-Receipt</b>	RFA approved by CPDO	04/26/2023	10/02/2023	
	RFA approved by CPDO (revised)	07/12/2023	10/02/2023	
	RFA published in Texas.gov eGrants	05/04/2023	10/02/2023	
	CPRIT Application Receipt System (CARS) opened	05/01/2023	10/02/2023	
	CPRIT Application Receipt System (CARS) closed	06/30/2023	10/02/2023	
	Date application submitted	05/29/2023	10/02/2023	
	Method of submission	CARS	10/02/2023	
	Within receipt period	YES	10/02/2023	
	Request for extension to submit application after CARS closed	N/A	10/02/2023	
	Request for extension for late application submission accepted	N/A	10/02/2023	
	Submission of application fee	YES	11/03/2023	
	<b>Receipt, Referral, and Assignment</b>	Administrative review notification	N/A	10/02/2023
		Donation(s) made to CPRIT / foundation	NO	10/02/2023
Assigned to primary reviewers		07/28/2023	10/02/2023	
Applicant notified of review panel assignment		07/25/2023	10/02/2023	
Primary Reviewer 1 COI signed		07/24/2023	10/02/2023	
Primary (Advocate) Reviewer 2 COI signed		07/21/2023	10/02/2023	
Primary Reviewer 3 COI signed		07/25/2023	10/02/2023	
Primary Reviewer 4 COI signed		07/26/2023	10/02/2023	
Primary Reviewer 5 COI signed		07/22/2023	10/02/2023	
Primary Reviewer 6 COI signed		07/21/2023	10/02/2023	
Primary Reviewer 7 COI signed		07/23/2023	10/02/2023	
Primary Reviewer 8 COI signed		07/21/2023	10/02/2023	
<b>Peer Review Meeting</b>		Primary Reviewer 1 critique submitted	08/24/2023	10/02/2023
	Primary (Advocate) Reviewer 2 critique submitted	08/23/2023	10/02/2023	
	Primary Reviewer 3 critique submitted	08/21/2023	10/02/2023	
	Primary Reviewer 4 critique submitted	08/21/2023	10/02/2023	
	Primary Reviewer 5 critique submitted	08/21/2023	10/02/2023	
	Primary Reviewer 6 critique submitted	08/01/2023	10/02/2023	
	Primary Reviewer 7 critique submitted	08/28/2023	10/02/2023	
	Primary Reviewer 8 critique submitted	08/29/2023	10/02/2023	
	COI indicated by non-primary reviewer	NONE	10/02/2023	
	COI recused from participation	N/A	10/02/2023	
	Peer Review Meeting	09/12/2023	10/02/2023	
	Post review statements signed	09/12/2023	10/02/2023	
	Third Party Observer Report	09/19/2023	10/02/2023	
<b>Due Diligence and IP Review</b>	Score report delivered to CPDO	09/13/2023	10/02/2023	
	Recommended for due diligence and IP review	YES	10/02/2023	
	Final due diligence review submitted to PDRC	10/18/2023	11/01/2023	
	Intellectual Property conflict check	07/11/2023	11/01/2023	
	Final intellectual property review submitted	10/04/2023	11/01/2023	
	COI indicated by reviewer	NONE	10/19/2023	
	COI recused from participation	N/A	10/19/2023	
	Due Diligence Meeting	10/11/2023	10/19/2023	
	Third Party Observer Report	10/15/2023	11/01/2023	
	Recommended for grant award	YES	10/19/2023	
	<b>Final PDRC Recommendation</b>	COI indicated by PDRC member	NONE	10/25/2023
		COI recused from participation	N/A	10/25/2023
		Due Diligence Evaluation Meeting / PDRC Meeting	N/A	10/25/2023
PDRC Meeting		10/24/2023	10/25/2023	
Third Party Observer Report		10/25/2023	11/02/2023	
Recommended for grant award		YES	10/25/2023	
PDRC Chair Notification to PIC and OC		10/24/2023	11/01/2023	
<b>PIC Review</b>	COI indicated by PIC member	None	11/01/2023	
	COI recused from participation	N/A	11/01/2023	
	PIC Review Meeting	11/01/2023	11/01/2023	
	Recommended for grant award	YES	11/01/2023	
<b>Oversight Committee Approval</b>	CEO Notification to Oversight Committee	11/03/2023	11/16/2023	
	COI Indicated by Oversight Committee member	None	11/16/2023	
	COI Recused from participation	N/A	11/16/2023	
	Donation(s) made to CPRIT / foundation	NO	11/16/2023	
	Presented to CPRIT Oversight Committee	11/15/2023	11/16/2023	
	Award approved by Oversight Committee	YES	11/16/2023	
	Authority to advance funds requested	YES	11/16/2023	
Advance authority approved by Oversight Committee	YES	11/16/2023		

# CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

## APPLICATION PEDIGREE

Date and time exported: 11/16/2023 10:51 AM CT

**FY:** 2024  
**CYCLE:** 1  
**PROGRAM:** Product Development  
**MECHANISM:** Texas New Technologies Company Full Awards for Product Development Research  
**APPLICATION ID:** DP240075  
**APPLICATION TITLE:** Mongoose Bio Memory TCR-T Cell Discovery and Therapeutics for Empirically Validated Tumor Targets  
**APPLICANT NAME:** Yee, Cassian  
**ORGANIZATION:** Mongoose Bio, LLC  
**PANEL NAME:** 24.1 Product Development Panel-5

Category	Compliance Requirement	Information	Attestation Date	
<b>Pre-Receipt</b>	RFA approved by CPDO	04/26/2023	10/02/2023	
	RFA approved by CPDO (revised)	07/12/2023	10/02/2023	
	RFA published in Texas.gov eGrants	05/04/2023	10/02/2023	
	CPRIT Application Receipt System (CARS) opened	05/01/2023	10/02/2023	
	CPRIT Application Receipt System (CARS) closed	06/30/2023	10/02/2023	
	Date application submitted	06/02/2023	10/04/2023	
	Method of submission	CARS	10/04/2023	
	Within receipt period	YES	10/04/2023	
	Request for extension to submit application after CARS closed	N/A	10/04/2023	
	Request for extension for late application submission accepted	N/A	10/04/2023	
	Submission of application fee	YES	11/03/2023	
	<b>Receipt, Referral, and Assignment</b>	Administrative review notification	07/12/2023	10/04/2023
		Donation(s) made to CPRIT / foundation	NO	10/04/2023
Assigned to primary reviewers		07/28/2023	10/04/2023	
Applicant notified of review panel assignment		07/25/2023	10/04/2023	
Primary Reviewer 1 COI signed		07/21/2023	10/04/2023	
Primary (Advocate) Reviewer 2 COI signed		07/21/2023	10/04/2023	
Primary Reviewer 3 COI signed		07/23/2023	10/04/2023	
Primary Reviewer 4 COI signed		07/21/2023	10/04/2023	
Primary Reviewer 5 COI signed		07/25/2023	10/04/2023	
Primary Reviewer 6 COI signed		07/23/2023	10/04/2023	
Primary Reviewer 7 COI signed		07/26/2023	10/04/2023	
Primary Reviewer 8 COI signed		07/21/2023	10/04/2023	
<b>Peer Review Meeting</b>		Primary Reviewer 1 critique submitted	08/28/2023	10/04/2023
	Primary (Advocate) Reviewer 2 critique submitted	08/26/2023	10/04/2023	
	Primary Reviewer 3 critique submitted	08/26/2023	10/04/2023	
	Primary Reviewer 4 critique submitted	08/29/2023	10/04/2023	
	Primary Reviewer 5 critique submitted	08/28/2023	10/04/2023	
	Primary Reviewer 6 critique submitted	08/01/2023	10/04/2023	
	Primary Reviewer 7 critique submitted	08/28/2023	10/04/2023	
	Primary Reviewer 8 critique submitted	08/07/2023	10/04/2023	
	COI indicated by non-primary reviewer	NONE	10/04/2023	
	COI recused from participation	N/A	10/04/2023	
	Peer Review Meeting	09/11/2023	10/04/2023	
	Post review statements signed	09/11/2023	10/04/2023	
	Third Party Observer Report	09/19/2023	10/04/2023	
Score report delivered to CPDO	09/12/2023	10/04/2023		
Recommended for due diligence and IP review	YES	10/04/2023		
<b>Due Diligence and IP Review</b>	Final due diligence review submitted to PDRC	10/18/2023	11/01/2023	
	Intellectual Property conflict check	07/11/2023	11/01/2023	
	Final intellectual property review submitted	10/03/2023	11/01/2023	
	COI indicated by reviewer	NONE	10/16/2023	
	COI recused from participation	N/A	10/16/2023	
	Due Diligence Meeting	10/10/2023	10/16/2023	
	Third Party Observer Report	10/15/2023	11/01/2023	
	Recommended for grant award	YES	10/16/2023	
<b>Final PDRC Recommendation</b>	COI indicated by PDRC member	NONE	10/25/2023	
	COI recused from participation	N/A	10/25/2023	
	Due Diligence Evaluation Meeting / PDRC Meeting	N/A	10/25/2023	
	PDRC Meeting	10/24/2023	10/25/2023	
	Third Party Observer Report	10/25/2023	11/02/2023	
	Recommended for grant award	YES	10/25/2023	
	PDRC Chair Notification to PIC and OC	10/24/2023	11/01/2023	
<b>PIC Review</b>	COI indicated by PIC member	None	11/01/2023	
	COI recused from participation	N/A	11/01/2023	
	PIC Review Meeting	11/01/2023	11/01/2023	
	Recommended for grant award	YES	11/01/2023	
<b>Oversight Committee Approval</b>	CEO Notification to Oversight Committee	11/03/2023	11/16/2023	
	COI Indicated by Oversight Committee member	None	11/16/2023	
	COI Recused from participation	N/A	11/16/2023	
	Donation(s) made to CPRIT / foundation	NO	11/16/2023	
	Presented to CPRIT Oversight Committee	11/15/2023	11/16/2023	
	Award approved by Oversight Committee	YES	11/16/2023	
	Authority to advance funds requested	YES	11/16/2023	
Advance authority approved by Oversight Committee	YES	11/16/2023		

# CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

## APPLICATION PEDIGREE

Date and time exported: 11/16/2023 10:51 AM CT

**FY:** 2024  
**CYCLE:** 1  
**PROGRAM:** Product Development  
**MECHANISM:** Texas Diagnostic and Devices Company Full Awards for Product Development Research  
**APPLICATION ID:** DP240088  
**APPLICATION TITLE:** FixNip NRI (Nipple Reconstruction Implant)  
**APPLICANT NAME:** Mizrachin, David  
**ORGANIZATION:** FixNip LTD.  
**PANEL NAME:** 24.1 Product Development Panel-13

Category	Compliance Requirement	Information	Attestation Date	
<b>Pre-Receipt</b>	RFA approved by CPDO	04/26/2023	10/02/2023	
	RFA approved by CPDO (revised)	07/12/2023	10/02/2023	
	RFA published in Texas.gov eGrants	05/04/2023	10/02/2023	
	CPRIT Application Receipt System (CARS) opened	05/01/2023	10/02/2023	
	CPRIT Application Receipt System (CARS) closed	06/30/2023	10/02/2023	
	Date application submitted	06/07/2023	10/03/2023	
	Method of submission	CARS	10/03/2023	
	Within receipt period	YES	10/03/2023	
	Request for extension to submit application after CARS closed	N/A	10/03/2023	
	Request for extension for late application submission accepted	N/A	10/03/2023	
	Submission of application fee	YES	11/03/2023	
	<b>Receipt, Referral, and Assignment</b>	Administrative review notification	07/12/2023	10/03/2023
		Donation(s) made to CPRIT / foundation	NO	10/03/2023
Assigned to primary reviewers		07/28/2023	10/03/2023	
Applicant notified of review panel assignment		07/25/2023	10/03/2023	
Primary Reviewer 1 COI signed		07/23/2023	10/03/2023	
Primary (Advocate) Reviewer 2 COI signed		07/21/2023	10/03/2023	
Primary Reviewer 3 COI signed		07/21/2023	10/03/2023	
Primary Reviewer 4 COI signed		07/21/2023	10/03/2023	
Primary Reviewer 5 COI signed		07/27/2023	10/03/2023	
Primary Reviewer 6 COI signed		08/28/2023	10/03/2023	
Primary Reviewer 7 COI signed		07/27/2023	10/03/2023	
Primary Reviewer 8 COI signed		07/21/2023	10/03/2023	
<b>Peer Review Meeting</b>		Primary Reviewer 1 critique submitted	08/28/2023	10/03/2023
	Primary (Advocate) Reviewer 2 critique submitted	08/28/2023	10/03/2023	
	Primary Reviewer 3 critique submitted	08/26/2023	10/03/2023	
	Primary Reviewer 4 critique submitted	08/09/2023	10/03/2023	
	Primary Reviewer 5 critique submitted	08/26/2023	10/03/2023	
	Primary Reviewer 6 critique submitted	08/29/2023	10/03/2023	
	Primary Reviewer 7 critique submitted	08/27/2023	10/03/2023	
	Primary Reviewer 8 critique submitted	08/26/2023	10/03/2023	
	COI indicated by non-primary reviewer	NONE	10/03/2023	
	COI recused from participation	N/A	10/03/2023	
	Peer Review Meeting	09/15/2023	10/03/2023	
	Post review statements signed	09/15/2023	10/03/2023	
	Third Party Observer Report	09/20/2023	10/03/2023	
	Score report delivered to CPDO	09/19/2023	10/03/2023	
	Recommended for due diligence and IP review	YES	10/03/2023	
<b>Due Diligence and IP Review</b>	Final due diligence review submitted to PDRC	10/18/2023	11/01/2023	
	Intellectual Property conflict check	07/12/2023	11/01/2023	
	Final intellectual property review submitted	10/03/2023	11/01/2023	
	COI indicated by reviewer	NONE	10/16/2023	
	COI recused from participation	N/A	10/16/2023	
	Due Diligence Meeting	10/11/2023	10/16/2023	
	Third Party Observer Report	10/16/2023	11/01/2023	
	Recommended for grant award	YES	10/16/2023	
<b>Final PDRC Recommendation</b>	COI indicated by PDRC member	NONE	10/25/2023	
	COI recused from participation	N/A	10/25/2023	
	Due Diligence Evaluation Meeting / PDRC Meeting	N/A	10/25/2023	
	PDRC Meeting	10/24/2023	10/25/2023	
	Third Party Observer Report	10/25/2023	11/02/2023	
	Recommended for grant award	YES	10/25/2023	
	PDRC Chair Notification to PIC and OC	10/24/2023	11/01/2023	
<b>PIC Review</b>	COI indicated by PIC member	None	11/01/2023	
	COI recused from participation	N/A	11/01/2023	
	PIC Review Meeting	11/01/2023	11/01/2023	
	Recommended for grant award	YES	11/01/2023	
<b>Oversight Committee Approval</b>	CEO Notification to Oversight Committee	11/03/2023	11/16/2023	
	COI Indicated by Oversight Committee member	None	11/16/2023	
	COI Recused from participation	N/A	11/16/2023	
	Donation(s) made to CPRIT / foundation	NO	11/16/2023	
	Presented to CPRIT Oversight Committee	11/15/2023	11/16/2023	
	Award approved by Oversight Committee	YES	11/16/2023	
	Authority to advance funds requested	YES	11/16/2023	
Advance authority approved by Oversight Committee	YES	11/16/2023		

# CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

## APPLICATION PEDIGREE

Date and time exported: 11/16/2023 10:51 AM CT

**FY:** 2024  
**CYCLE:** 1  
**PROGRAM:** Product Development  
**MECHANISM:** Texas Therapeutics Company Full Awards for Product Development Research  
**APPLICATION ID:** DP240091  
**APPLICATION TITLE:** Gradalis, Inc. - Vigil maintenance in PS ovarian patients  
**APPLICANT NAME:** Nemunaitis (g1), John J  
**ORGANIZATION:** Gradalis  
**PANEL NAME:** 24.1 Product Development Panel-7

Category	Compliance Requirement	Information	Attestation Date	
<b>Pre-Receipt</b>	RFA approved by CPDO	04/26/2023	10/02/2023	
	RFA approved by CPDO (revised)	07/12/2023	10/02/2023	
	RFA published in Texas.gov eGrants	05/04/2023	10/02/2023	
	CPRIT Application Receipt System (CARS) opened	05/01/2023	10/02/2023	
	CPRIT Application Receipt System (CARS) closed	06/30/2023	10/02/2023	
	Date application submitted	06/13/2023	10/02/2023	
	Method of submission	CARS	10/02/2023	
	Within receipt period	YES	10/02/2023	
	Request for extension to submit application after CARS closed	N/A	10/02/2023	
	Request for extension for late application submission accepted	N/A	10/02/2023	
	Submission of application fee	YES	11/03/2023	
	<b>Receipt, Referral, and Assignment</b>	Administrative review notification	07/12/2023	10/02/2023
		Donation(s) made to CPRIT / foundation	NO	10/02/2023
Assigned to primary reviewers		07/28/2023	10/02/2023	
Applicant notified of review panel assignment		07/25/2023	10/02/2023	
Primary Reviewer 1 COI signed		07/21/2023	10/02/2023	
Primary (Advocate) Reviewer 2 COI signed		07/21/2023	10/02/2023	
Primary Reviewer 3 COI signed		07/21/2023	10/02/2023	
Primary Reviewer 4 COI signed		08/21/2023	10/02/2023	
Primary Reviewer 5 COI signed		07/21/2023	10/02/2023	
Primary Reviewer 6 COI signed		07/21/2023	10/02/2023	
Primary Reviewer 7 COI signed		07/25/2023	10/02/2023	
Primary Reviewer 8 COI signed		07/21/2023	10/02/2023	
<b>Peer Review Meeting</b>		Primary Reviewer 1 critique submitted	08/18/2023	10/02/2023
	Primary (Advocate) Reviewer 2 critique submitted	08/13/2023	10/02/2023	
	Primary Reviewer 3 critique submitted	08/26/2023	10/02/2023	
	Primary Reviewer 4 critique submitted	08/27/2023	10/02/2023	
	Primary Reviewer 5 critique submitted	08/21/2023	10/02/2023	
	Primary Reviewer 6 critique submitted	08/26/2023	10/02/2023	
	Primary Reviewer 7 critique submitted	08/14/2023	10/02/2023	
	Primary Reviewer 8 critique submitted	08/18/2023	10/02/2023	
	COI indicated by non-primary reviewer	NONE	10/02/2023	
	COI recused from participation	N/A	10/02/2023	
	Peer Review Meeting	09/12/2023	10/02/2023	
	Post review statements signed	09/12/2023	10/02/2023	
	Third Party Observer Report	09/19/2023	10/02/2023	
<b>Due Diligence and IP Review</b>	Score report delivered to CPDO	09/13/2023	10/02/2023	
	Recommended for due diligence and IP review	YES	10/02/2023	
	Final due diligence review submitted to PDRC	10/18/2023	11/01/2023	
	Intellectual Property conflict check	07/12/2023	11/01/2023	
	Final intellectual property review submitted	10/02/2023	11/01/2023	
	COI indicated by reviewer	NONE	10/16/2023	
	COI recused from participation	N/A	10/16/2023	
	Due Diligence Meeting	10/10/2023	10/16/2023	
	Third Party Observer Report	10/15/2023	11/01/2023	
	Recommended for grant award	YES	10/16/2023	
	<b>Final PDRC Recommendation</b>	COI indicated by PDRC member	NONE	10/25/2023
		COI recused from participation	N/A	10/25/2023
		Due Diligence Evaluation Meeting / PDRC Meeting	N/A	10/25/2023
PDRC Meeting		10/24/2023	10/25/2023	
Third Party Observer Report		10/25/2023	11/02/2023	
Recommended for grant award		YES	10/25/2023	
PDRC Chair Notification to PIC and OC		10/24/2023	11/01/2023	
<b>PIC Review</b>	COI indicated by PIC member	None	11/01/2023	
	COI recused from participation	N/A	11/01/2023	
	PIC Review Meeting	11/01/2023	11/01/2023	
	Recommended for grant award	YES	11/01/2023	
<b>Oversight Committee Approval</b>	CEO Notification to Oversight Committee	11/03/2023	11/16/2023	
	COI Indicated by Oversight Committee member	None	11/16/2023	
	COI Recused from participation	N/A	11/16/2023	
	Donation(s) made to CPRIT / foundation	NO	11/16/2023	
	Presented to CPRIT Oversight Committee	11/15/2023	11/16/2023	
	Award approved by Oversight Committee	YES	11/16/2023	
	Authority to advance funds requested	YES	11/16/2023	
Advance authority approved by Oversight Committee	YES	11/16/2023		

# CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

## APPLICATION PEDIGREE

Date and time exported: 11/16/2023 10:51 AM CT

**FY:** 2024  
**CYCLE:** 1  
**PROGRAM:** Product Development  
**MECHANISM:** Texas Therapeutics Company Full Awards for Product Development Research  
**APPLICATION ID:** DP240095  
**APPLICATION TITLE:** A Phase 1-2 clinical study to evaluate SR-8541A plus balstilimab and botensilimab in MSS CRC patients  
**APPLICANT NAME:** Northrup, Jonathan  
**ORGANIZATION:** Stingray Therapeutics, Inc.  
**PANEL NAME:** 24.1 Product Development Panel-9

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA approved by CPDO	04/26/2023	10/02/2023	
	RFA approved by CPDO (revised)	07/12/2023	10/02/2023	
	RFA published in Texas.gov eGrants	05/04/2023	10/02/2023	
	CPRIT Application Receipt System (CARS) opened	05/01/2023	10/02/2023	
	CPRIT Application Receipt System (CARS) closed	06/30/2023	10/02/2023	
	Date application submitted	06/14/2023	10/03/2023	
	Method of submission	CARS	10/03/2023	
	Within receipt period	YES	10/03/2023	
	Request for extension to submit application after CARS closed	N/A	10/03/2023	
	Request for extension for late application submission accepted	N/A	10/03/2023	
	Submission of application fee	YES	11/03/2023	
	Receipt, Referral, and Assignment	Administrative review notification	07/12/2023	10/03/2023
		Donation(s) made to CPRIT / foundation	NO	10/03/2023
Assigned to primary reviewers		07/28/2023	10/03/2023	
Applicant notified of review panel assignment		07/25/2023	10/03/2023	
Primary Reviewer 1 COI signed		07/26/2023	10/03/2023	
Primary (Advocate) Reviewer 2 COI signed		07/21/2023	10/03/2023	
Primary Reviewer 3 COI signed		07/25/2023	10/03/2023	
Primary Reviewer 4 COI signed		07/23/2023	10/03/2023	
Primary Reviewer 5 COI signed		07/22/2023	10/03/2023	
Primary Reviewer 6 COI signed		07/24/2023	10/03/2023	
Primary Reviewer 7 COI signed		07/27/2023	10/03/2023	
Primary Reviewer 8 COI signed		07/24/2023	10/03/2023	
Primary Reviewer 9 COI signed		07/21/2023	10/03/2023	
Peer Review Meeting		Primary Reviewer 1 critique submitted	08/28/2023	10/03/2023
	Primary (Advocate) Reviewer 2 critique submitted	08/17/2023	10/03/2023	
	Primary Reviewer 3 critique submitted	08/16/2023	10/03/2023	
	Primary Reviewer 4 critique submitted	08/22/2023	10/03/2023	
	Primary Reviewer 5 critique submitted	08/28/2023	10/03/2023	
	Primary Reviewer 6 critique submitted	08/28/2023	10/03/2023	
	Primary Reviewer 7 critique submitted	08/31/2023	10/03/2023	
	Primary Reviewer 8 critique submitted	08/27/2023	10/03/2023	
	Primary Reviewer 9 critique submitted	08/20/2023	10/03/2023	
	COI indicated by non-primary reviewer	NONE	10/03/2023	
	COI recused from participation	N/A	10/03/2023	
	Peer Review Meeting	09/13/2023	10/03/2023	
	Post review statements signed	09/15/2023	10/03/2023	
	Third Party Observer Report	09/19/2023	10/03/2023	
Score report delivered to CPDO	09/19/2023	10/03/2023		
Recommended for due diligence and IP review	YES	10/03/2023		
Due Diligence and IP Review	Final due diligence review submitted to PDRC	10/18/2023	11/01/2023	
	Intellectual Property conflict check	07/11/2023	11/01/2023	
	Final intellectual property review submitted	10/04/2023	11/01/2023	
	COI indicated by reviewer	NONE	10/16/2023	
	COI recused from participation	N/A	10/16/2023	
	Due Diligence Meeting	10/11/2023	10/16/2023	
	Third Party Observer Report	10/16/2023	11/01/2023	
	Recommended for grant award	YES	10/16/2023	
Final PDRC Recommendation	COI indicated by PDRC member	NONE	10/25/2023	
	COI recused from participation	N/A	10/25/2023	
	Due Diligence Evaluation Meeting / PDRC Meeting	N/A	10/25/2023	
	PDRC Meeting	10/24/2023	10/25/2023	
	Third Party Observer Report	10/25/2023	11/02/2023	
	Recommended for grant award	YES	10/25/2023	
	PDRC Chair Notification to PIC and OC	10/24/2023	11/01/2023	
PIC Review	COI indicated by PIC member	None	11/01/2023	
	COI recused from participation	N/A	11/01/2023	
	PIC Review Meeting	11/01/2023	11/01/2023	
	Recommended for grant award	YES	11/01/2023	
Oversight Committee Approval	CEO Notification to Oversight Committee	11/03/2023	11/16/2023	
	COI Indicated by Oversight Committee member	None	11/16/2023	
	COI Recused from participation	N/A	11/16/2023	
	Donation(s) made to CPRIT / foundation	NO	11/16/2023	
	Presented to CPRIT Oversight Committee	11/15/2023	11/16/2023	
	Award approved by Oversight Committee	YES	11/16/2023	
	Authority to advance funds requested	YES	11/16/2023	
	Advance authority approved by Oversight Committee	YES	11/16/2023	

# CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

## APPLICATION PEDIGREE

Date and time exported: 11/16/2023 10:52 AM CT

**FY:** 2024  
**CYCLE:** 1  
**PROGRAM:** Product Development  
**MECHANISM:** Seed Full Awards for Product Development Research  
**APPLICATION ID:** DP240117  
**APPLICATION TITLE:** A Novel High Throughput Platform for Drug Screening Against Dormant and Migrating High-Grade Glioma Cells  
**APPLICANT NAME:** Dave, Digant P  
**ORGANIZATION:** Single Cell Biotechnology Inc.  
**PANEL NAME:** 24.1 Product Development Panel-4

Category	Compliance Requirement	Information	Attestation Date	
<b>Pre-Receipt</b>	RFA approved by CPDO	04/26/2023	10/02/2023	
	RFA approved by CPDO (revised)	07/12/2023	10/02/2023	
	RFA published in Texas.gov eGrants	05/04/2023	10/02/2023	
	CPRIT Application Receipt System (CARS) opened	05/01/2023	10/02/2023	
	CPRIT Application Receipt System (CARS) closed	06/30/2023	10/02/2023	
	Date application submitted	06/30/2023	10/02/2023	
	Method of submission	CARS	10/02/2023	
	Within receipt period	YES	10/02/2023	
	Request for extension to submit application after CARS closed	N/A	10/02/2023	
	Request for extension for late application submission accepted	N/A	10/02/2023	
	Submission of application fee	YES	11/03/2023	
	<b>Receipt, Referral, and Assignment</b>	Administrative review notification	N/A	10/02/2023
		Donation(s) made to CPRIT / foundation	NO	10/02/2023
Assigned to primary reviewers		07/03/2023	10/02/2023	
Applicant notified of review panel assignment		07/03/2023	10/02/2023	
Primary Reviewer 1 COI signed		07/02/2023	10/02/2023	
Primary (Advocate) Reviewer 2 COI signed		07/02/2023	10/02/2023	
Primary Reviewer 3 COI signed		06/30/2023	10/02/2023	
Primary Reviewer 4 COI signed		06/30/2023	10/02/2023	
Primary Reviewer 5 COI signed		07/01/2023	10/02/2023	
Primary Reviewer 6 COI signed		06/30/2023	10/02/2023	
Primary Reviewer 7 COI signed		07/01/2023	10/02/2023	
Primary Reviewer 8 COI signed		06/30/2023	10/02/2023	
<b>Peer Review Meeting</b>		Primary Reviewer 1 critique submitted	07/12/2023	10/02/2023
	Primary (Advocate) Reviewer 2 critique submitted	07/14/2023	10/02/2023	
	Primary Reviewer 3 critique submitted	08/01/2023	10/02/2023	
	Primary Reviewer 4 critique submitted	07/26/2023	10/02/2023	
	Primary Reviewer 5 critique submitted	07/25/2023	10/02/2023	
	Primary Reviewer 6 critique submitted	07/22/2023	10/02/2023	
	Primary Reviewer 7 critique submitted	07/15/2023	10/02/2023	
	Primary Reviewer 8 critique submitted	07/12/2023	10/02/2023	
	COI indicated by non-primary reviewer	NONE	10/02/2023	
	COI recused from participation	N/A	10/02/2023	
	Peer Review Meeting	08/11/2023	10/02/2023	
	Post review statements signed	08/11/2023	10/02/2023	
	Third Party Observer Report	08/17/2023	10/02/2023	
Score report delivered to CPDO	08/15/2023	10/02/2023		
Recommended for due diligence and IP review	YES	10/02/2023		
<b>Due Diligence and IP Review</b>	Final due diligence review submitted to PDRC	10/18/2023	11/01/2023	
	Intellectual Property conflict check	07/12/2023	11/01/2023	
	Final intellectual property review submitted	08/31/2023	11/01/2023	
	COI indicated by reviewer	NONE	10/02/2023	
	COI recused from participation	N/A	10/02/2023	
	Due Diligence Meeting	09/08/2023	10/02/2023	
	Third Party Observer Report	09/12/2023	11/01/2023	
Recommended for grant award	YES	10/02/2023		
<b>Final PDRC Recommendation</b>	COI indicated by PDRC member	NONE	10/25/2023	
	COI recused from participation	N/A	10/25/2023	
	Due Diligence Evaluation Meeting / PDRC Meeting	N/A	10/02/2023	
	PDRC Meeting	10/24/2023	10/25/2023	
	Third Party Observer Report	10/25/2023	11/02/2023	
	Recommended for grant award	YES	10/25/2023	
	PDRC Chair Notification to PIC and OC	10/24/2023	11/01/2023	
<b>PIC Review</b>	COI indicated by PIC member	None	11/01/2023	
	COI recused from participation	N/A	11/01/2023	
	PIC Review Meeting	11/01/2023	11/01/2023	
	Recommended for grant award	YES	11/01/2023	
<b>Oversight Committee Approval</b>	CEO Notification to Oversight Committee	11/03/2023	11/16/2023	
	COI Indicated by Oversight Committee member	None	11/16/2023	
	COI Recused from participation	N/A	11/16/2023	
	Donation(s) made to CPRIT / foundation	NO	11/16/2023	
	Presented to CPRIT Oversight Committee	11/15/2023	11/16/2023	
	Award approved by Oversight Committee	YES	11/16/2023	
	Authority to advance funds requested	YES	11/16/2023	
	Advance authority approved by Oversight Committee	YES	11/16/2023	

Comments:  
 Comment  
 On 8/11/2023, DP240117 was recommended to Due Diligence, not Review Council Discussion, as the Due Diligence and Review Council meetings are now se

CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE Date and time exported: 11/16/2023 10:57 AM CT

FY:	2024			
CYCLE:	1			
PROGRAM:	Recruitment			
MECHANISM:	Recruitment of First-Time, Tenure-Track Faculty Members			
APPLICATION ID:	RR240005			
APPLICATION TITLE:	Personalized therapies for glioblastoma using multifunctional hydrogel platforms			
APPLICANT NAME:	Tringides, Christina			
ORGANIZATION:	Rice University			
PANEL NAME:	Recruitment FY24_Cycle 1 and 2			
Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	06/20/2023	09/29/2023	
	RFA published in Texas.gov eGrants	06/22/2023	09/29/2023	
	CPRIT Application Receipt Cycle opened	06/21/2023	09/29/2023	
	CPRIT Application Receipt Cycle closed	07/20/2023	09/29/2023	
	Date application submitted	07/20/2023	09/29/2023	
	Method of submission	CARS	09/29/2023	
	Within receipt period	YES	09/29/2023	
	Administrative review notification	08/01/2023	09/29/2023	
	Donation(s) made to CPRIT / foundation	NO	09/29/2023	
	Assigned to primary reviewers	09/01/2023	09/29/2023	
Receipt, Referral, and Assignment	Applicant notified of review panel assignment	N/A	09/29/2023	
	Primary Reviewer 1 COI signed	08/31/2023	09/29/2023	
	Primary Reviewer 2 COI signed	08/24/2023	09/29/2023	
	Primary Reviewer 1 critique submitted	09/13/2023	09/29/2023	
	Primary Reviewer 2 critique submitted	09/11/2023	09/29/2023	
	COI indicated by non-primary reviewer	NONE	09/29/2023	
	COI recused from participation	N/A	09/29/2023	
	Discussed at Peer Review Meeting	YES	09/29/2023	
	Peer Review Meeting	09/14/2023	09/29/2023	
	Post review statements signed	09/15/2023	09/29/2023	
Peer Review Meeting	Third Party Observer Report	09/20/2023	10/24/2023	
	Score report delivered to CSO	09/22/2023	09/29/2023	
	Recommended for SRC review	YES	09/29/2023	
	COI indicated by SRC member	NONE	09/29/2023	
	COI recused from participation	N/A	09/29/2023	
	SRC Meeting	09/14/2023	09/29/2023	
	Third Party Observer Report	09/20/2023	10/24/2023	
	Recommended for grant award	YES	09/29/2023	
	SRC Chair Notification to PIC and OC	10/20/2023	10/24/2023	
	Candidate not accepted asst. prof. tenure track position prior to SRC date	YES	11/01/2023	
PIC Review	COI indicated by PIC member	None	11/01/2023	
	COI recused from participation	N/A	11/01/2023	
	PIC Review Meeting	11/01/2023	11/01/2023	
	Recommended for grant award	YES	11/01/2023	
	11/03/2023	11/16/2023		
Oversight Committee Approval	CEO Notification to Oversight Committee	None	11/16/2023	
	COI Indicated by Oversight Committee member	N/A	11/16/2023	
	COI Recused from participation	NO	11/16/2023	
	Donation(s) made to CPRIT / foundation	11/15/2023	11/16/2023	
	Presented to CPRIT Oversight Committee	YES	11/16/2023	
	Award approved by Oversight Committee	NO	11/16/2023	
	Authority to advance funds requested	NO	11/16/2023	
	Advance authority approved by Oversight Committee	NO	11/16/2023	
	Comments:			
	Comment			Created Date
No Comment				

CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE Date and time exported: 11/16/2023 10:57 AM CT

FY:	2024		
CYCLE:	1		
PROGRAM:	Recruitment		
MECHANISM:	Recruitment of Established Investigators		
APPLICATION ID:	RR240012		
APPLICATION TITLE:	Bone Marrow Microenvironment as Target and Source for Immunotherapy		
APPLICANT NAME:	Luznik, Leonido		
ORGANIZATION:	Baylor College of Medicine		
PANEL NAME:	Recruitment FY24_Cycle 1 and 2		
Category		Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	06/20/2023	09/29/2023
	RFA published in Texas.gov eGrants	06/22/2023	09/29/2023
	CPRIT Application Receipt Cycle opened	06/21/2023	09/29/2023
	CPRIT Application Receipt Cycle closed	07/20/2023	09/29/2023
	CPRIT Application Receipt Cycle opened - 24.2	07/21/2023	09/29/2023
	CPRIT Application Receipt Cycle closed - 24.2	08/21/2023	09/29/2023
	Date application submitted	08/18/2023	09/29/2023
	Method of submission	CARS	09/29/2023
	Within receipt period	YES	09/29/2023
	Receipt, Referral, and Assignment	Administrative review notification	08/25/2023
Donation(s) made to CPRIT / foundation		NO	09/29/2023
Assigned to primary reviewers		09/01/2023	09/29/2023
Applicant notified of review panel assignment		N/A	09/29/2023
Primary Reviewer 1 COI signed		08/25/2023	09/29/2023
Primary Reviewer 2 COI signed		08/23/2023	09/29/2023
		09/13/2023	09/29/2023
		09/04/2023	09/29/2023
Peer Review Meeting	Primary Reviewer 1 critique submitted	09/04/2023	09/29/2023
	Primary Reviewer 2 critique submitted	NONE	09/29/2023
	COI indicated by non-primary reviewer	N/A	09/29/2023
	COI recused from participation	YES	09/29/2023
	Discussed at Peer Review Meeting	09/14/2023	09/29/2023
	Peer Review Meeting	09/15/2023	09/29/2023
	Post review statements signed	09/20/2023	10/24/2023
	Third Party Observer Report	09/22/2023	09/29/2023
	Score report delivered to CSO	YES	09/29/2023
	Recommended for SRC review	NONE	09/29/2023
Final SRC Recommendation	COI indicated by SRC member	N/A	09/29/2023
	COI recused from participation	09/14/2023	09/29/2023
	SRC Meeting	09/20/2023	10/24/2023
	Third Party Observer Report	YES	09/29/2023
	Recommended for grant award	10/20/2023	10/24/2023
	SRC Chair Notification to PIC and OC	YES	11/01/2023
PIC Review	Candidate not accepted position prior to SRC date	None	11/01/2023
	COI indicated by PIC member	N/A	11/01/2023
	COI recused from participation	11/01/2023	11/01/2023
	PIC Review Meeting	YES	11/01/2023
	Recommended for grant award	11/03/2023	11/16/2023
Oversight Committee Approval	CEO Notification to Oversight Committee	None	11/16/2023
	COI Indicated by Oversight Committee member	N/A	11/16/2023
	COI Recused from participation	NO	11/16/2023
	Donation(s) made to CPRIT / foundation	11/15/2023	11/16/2023
	Presented to CPRIT Oversight Committee	YES	11/16/2023
	Award approved by Oversight Committee	NO	11/16/2023
	Authority to advance funds requested	NO	11/16/2023
Advance authority approved by Oversight Committee	NO	11/16/2023	
Comments:			
Comment			Created Date
No Comment			